Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. reports developments tied to its PetMeds pet pharmacy platform, its PetCareRx business, and the sale of prescription and non-prescription pet medications, preventatives, health products, and supplies. The company serves pet owners through direct-to-consumer channels and has announced distribution partnerships that extend pet pharmacy offerings across retail and digital channels.
Recurring news themes include product assortments focused on pet wellness, fiscal results and financial reporting updates, Nasdaq listing-rule communications related to periodic filings, board and audit committee changes, shareholder rights plan actions, and responses to unsolicited acquisition proposals. Coverage also reflects the company's positioning as a national pet pharmacy and pet health products retailer.
PetMeds (Nasdaq: PETS) unveiled its 2025 Holiday Collection on December 10, 2025: a curated assortment of wellness-focused gifts for pets and pet parents emphasizing health, safety, and everyday comfort.
The collection highlights grooming items, first-aid and screening tests (including an at-home cancer urine test and multiple DNA tests), toys, treats, cat monitoring devices, equine grooming and supplements, and natural pest-repellent collars. The Holiday Giftable Essentials Collection is available now at PetMeds.com with fast shipping and subscription options for select items.
PetMeds (Nasdaq: PETS) announced that its Board unanimously approved an amendment extending the company’s existing shareholder rights plan by one year, moving the expiration from December 2, 2025 to December 2, 2026. All other terms remain unchanged.
The Board said the extension is intended to protect shareholders while it believes the stock does not reflect the company’s inherent value and because of recent significant accumulations of company common stock by certain shareholders. The Rights Plan is intended to ensure fair treatment and to guard against acquisitions without payment of an appropriate control premium. A Form 8-K will provide further details.
PetMed Express (Nasdaq: PETS) announced preliminary fiscal Q2 2026 results and filed a Form 12b-25 notifying the SEC of a late 10-Q filing for the quarter ended September 30, 2025. The Company estimates Q2 net sales of $43.4M–$44.5M versus $58.0M in the prior year and six-month net sales of $94.5M–$95.6M versus $124.3M prior. The company reported $36.1M cash and no debt as of September 30, 2025.
The Company cannot yet estimate operating or net income while it analyzes the timing and amount of an anticipated goodwill impairment. Nasdaq sent a notice of non-compliance; the company must update its plan by November 28, 2025, and any Nasdaq exception may be limited to December 29, 2025. The notice does not have an immediate effect on the stock listing.
PetMed Express (Nasdaq: PETS) appointed James LaCamp to its Board effective immediately and named him Chair of the Audit Committee, effective October 30, 2025. Mr. LaCamp qualifies as an audit committee financial expert and brings nearly two decades of finance, accounting, and audit experience including 12+ years as an audit partner at Deloitte.
The Board now has six directors, five independent, and has added four directors since 2024 as part of ongoing board refreshment.
PetMeds (NASDAQ: PETS) filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
Key fiscal 2025 results: net sales $227.0 million (below prior preliminary range of $231.6–$233.6 million), net loss $6.3 million (wider than prior preliminary $4.5–$5.0 million), and cash $54.7 million with no debt. The company recorded a $1.2 million non-cash intangible impairment and restated promotional sales reimbursements from revenue to cost of sales, which the company says did not affect net income.
Management said it will file Form 10-Q for Q1 ended June 30, 2025 and subsequent quarterly filings "as soon as practicable" but gave no firm dates.
PetMed Express (NASDAQ: PETS) announced a September 9, 2025 award of 15,000 restricted common shares to Ali Khan upon his hiring as Chief Information Security Officer. The grant was made under the 2024 Inducement Incentive Plan and designated a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The shares vest in equal one-third increments on each of the first three anniversaries of the vesting commencement date, August 20, 2025, subject to continued employment.
PetMed Express (NASDAQ: PETS) announced significant leadership changes as CEO Sandra Campos and CFO Robyn D'Elia have resigned from their positions. Board Chair Leslie C.G. Campbell has been appointed as Interim CEO, while Chief Accounting Officer Douglas Krulik will serve as Interim Principal Financial Officer.
The departing executives will receive 13 months of base salary continuation and accelerated vesting of certain restricted stock units as severance, along with providing consulting services for three months. The company has initiated a search for permanent CEO and CFO positions. The Board has been restructured with Justin Mennen appointed as Lead Independent Director, while Peter Batushansky and Leah Solivan will chair the Audit and Compensation committees respectively.
PetMeds (NASDAQ: PETS) has partnered with myBalto Foundation for their "Top of the Class" fundraising drive, successfully raising nearly $45,000 to help pet owners cover emergency veterinary costs. The initiative aims to support myBalto's Angel Fund program, which assists veterinary hospitals in providing financial aid to pet parents facing hardships.
As part of the partnership, PetMeds offered 25% discounts to donors to encourage community participation. The myBalto Foundation provides veterinary hospitals with free Angel Funds, eliminating administrative burdens while enabling quick financial support for pet owners during emergency situations.
PetMed Express (NASDAQ: PETS) has received a notification from Nasdaq on July 2, 2025, regarding non-compliance with listing rules due to delayed filing of its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
The company has until September 1, 2025 to submit a compliance plan to Nasdaq, which may grant an extension until December 29, 2025 to regain compliance. PetMeds previously filed a Form 12b-25 on June 16, 2025, citing the need for additional time to compile and analyze financial information. The notice has no immediate impact on the company's Nasdaq listing status.
PetMed Express (NASDAQ: PETS), operating as PetMeds and parent company of PetCareRx, announced it will be unable to file its Form 10-K for FY 2025 within the extension period ending July 1, 2025. The delay is due to an ongoing investigation initiated by the Audit Committee following anonymous whistleblower reports.
The whistleblower complaints concern three main issues: revenue recognition timing for certain autoship orders in Q4 2025 that led to customer complaints, a $50 coupon promotion's impact on new customer KPIs, and concerns about the company's culture and control environment. The Audit Committee has engaged external legal counsel and advisors to investigate these matters.
Despite the ongoing investigation, PetMed Express states that based on current evidence, they do not expect the investigation to materially impact their previously announced preliminary Q4 and FY 2025 financial results or previously filed financial statements.
[ "Company does not expect material impact on previously announced financial results", "External legal counsel and advisors engaged for thorough investigation", "Company has established whistleblower reporting system in place" ]